Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Global Organization That will Buy And Distribute B-COVID

History & Mission
In April 2020, at an event convened by the World Health Organization (WHO), France, the European Commission, and the Bill & Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator was launched to help the global community combat the COVID-19 pandemic. The ACT Accelerator brings together governments, scientific and regulatory experts, philanthropies, and global health organizations to focus on four main pillars: 1) diagnostics, 2) treatment, 3) vaccines, and 4) health systems strengthening. Each of the pillars is led and coordinated by different multilateral institutions.

https://www.kff.org/coronavirus-covid-19/issue-brief/covax-and-the-united-states/#:~:text=On%20January%2021%2C%202021,on%20COVID%2D19.

Therapeutics
Therapeutics can play a role in all stages of COVID-19 disease: to prevent infection; suppress symptoms and spread of infection to others; treat or prevent symptoms; as a life-saving treatment for severe symptoms; and as a treatment that can speed up recovery. The aim in the next 12 months is to develop, manufacture and distribute 245 million treatments, helping COVID-19 sufferers to recover from the disease. The therapeutics pillar is led by Unitaid and Wellcome.

Therapeutics Investment Case

Led by Wellcome?and?Unitaid?.

https://www.who.int/initiatives/act-accelerator/about

The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic collaboration supporting efforts to research, develop and bring effective treatments against COVID-19 to market quickly and accessibly.

Currently, there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and very few treatments approved for use against COVID-19.

To effectively address COVID-19, the world will require multiple prevention and treatment options. The CTA is working to coordinate R&D efforts to help remove barriers to drug development and scale up interventions that can be used as prophylactics or to treat mild and moderate forms of COVID-19.

The CTA coordinates with the Therapeutics Partnership of the Access to COVID-19 Tools Accelerator (ACT-A) working with the World Health Organization, the global research community, governments, private sector organizations, and global regulators to help accelerate development of safe, effective and accessible drugs.

The CTA’s governance model allows participating organizations to provide fast and flexible funding to help remove bottlenecks in the drug development and scale-up process. [Possible funding source for B-COVID/P-3?]

The CTA puts equity at the core of its approach. Coordinating organizations are committed to ensuring that the innovations supported are available and affordable in low-resource settings.

https://www.therapeuticsaccelerator.org/

The last paragraph in the quote above is very important to IPIX because the lower-income countries are numerous and represent a potential logistical nightmare. The high-income countries are "low-hanging fruit" because all they require is delivery of product and they will distribute themselves.

From IPIX's perspective, dealing with the 'COVID-19 Therapeutics Accelerator' (CTA), who will supply the lower-income countries, will be akin to IPIX dealing with a high-income country.

As I alluded to earlier, CTA could also be a source of funding:

As of October 26th, 2020, the COVID-19 Therapeutics Accelerator has awarded over $98 million in grants.

https://www.therapeuticsaccelerator.org/investments-made/

CTA is a potential billion-dollar buyer of B-COVID for lower-income countries and has stated a willingness to help with development and manufacturing costs in addition to worldwide distribution.

I don't know if B-COVID is on CTA's radar yet. I feel certain it will be on their radar shortly. I think, inevitably, CTA and IPIX are locked onto a collision course that will greatly benefit mankind and shareholders alike.

IPIX doesn't need "Big Pharma" to make this happen.